U.S. SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, D.C.

                                   FORM 12b-25

NOTIFICATION OF LATE FILING                     SEC File Number 0-24641

[X] Form 10-K and Form 10-KSB [ ] Form 20-F [ ] Form 10-Q and Form 10-QSB [ ]
Form N-SAR

    For Period Ended: June 30, 2004

      [ ] Transition Report on Form 10-Q
      [ ] Transition Report on Form 10-K
      [ ] Transition Report on Form N-SAR
      [ ] Transition Report on Form 20-F
      [ ] Transition Report on Form 11-K

    For the Transition Period Ended:
================================================================================
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
================================================================================
If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
================================================================================
                         Part I - Registrant Information
================================================================================
Full Name of Registrant: IMMUNOTECHNOLOGY CORPORATION

Former Name if applicable: N/A

Address of Principal Executive Office:
1661 Lakeview Circle
Ogden, UT 84403

================================================================================
                        Part II - Rules 12b-25(b) and (c)
================================================================================
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed.

[ ] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;

[x] (b) The subject annual report, semi-annual report, transition report on Form
10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the fifteenth calendar day following the prescribed due date; or the
subject quarterly report or transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following the prescribed due
date; and

[ ] (c) The accountant's statement or other exhibit required by Rule 12b- 25(c)
has been attached if applicable.

================================================================================






                              Part III - Narrative
================================================================================

State below in reasonable detail the reasons why Form 10-K and Form 10-KSB,
20-F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion
thereof could not be filed within the prescribed period.

     Certain aspects of the registrant's review process have not been completed
prior to the filing date.

================================================================================
                           Part IV - Other Information
================================================================================
     (1) Name and telephone number of person to contact in regard to this
notification:

      Mr. Mark Scharmann 1661 Lakeview Circle Ogden, UT 84403 Phone:
      801-399-3632

     (2) Have all other periodic reports required under section 13 or 15(d) of
the Securities Exchange Act of 1934 or section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).

              [x] Yes    [ ] No

     (3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

              [ ] Yes    [X] No    Presently unknown.

     If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.

Immunotechnology Corporation has caused this notification to be signed on its
behalf by the undersigned thereunto duly authorized.

Date: September 29, 2004               By:  /s/Mark Scharmann
                                       President and Director
                                       Principal Executive and Financial Officer

================================================================================
                                    ATTENTION

     Intentional  misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).

                                       2